For example, a previous study reported that 40.6% of CVD patients who received five or more CVD drugs presented cardiovascular polypharmacy. 15 Although
Subgroup analyses were conducted to investigate the associations of (1) stimulant and nonstimulant medications with any CVD, (2) ADHD medications with specific CVD (ie, cardiac arrest or tachyarrhythmias, cerebrovascular disease, myocardial infarction), (3) stimulant ADHD medications with specific CVD, (4) ADHD medications with any CVD in
PSYCHOSOMATICS Addressing Depression Symptoms The Use of Statins in Schizophrenia Depression, Anxiety, and CVD Risk of Drug-Drug
India shoulders the greatest global burden of cardiovascular diseases (CVDs), which are the leading cause of mortality worldwide. Drugs are the bedrock of treatment and prevention of CVD. India s pharmaceutical industry is the third largest, by
Some patients cannot tolerate statins, but there are several other classes of drugs that can lower LDL cholesterol. People without CVD People without a history of cardiovascular disease (CVD) also benefit from cholesterol-lowering therapy, although the goal is generally not as aggressive as in people with CVD. The decision of whether to
Cardiovascular disease (CVD) is any disease involving the heart or blood vessels. CVDs constitute a class of diseases that includes: coronary artery
Diabetes 1% Cardiovascular Stroke 33% Other cancers 20% Male CVD thiazolidinediones) Public health Appreciation that risk of CVD
Further preventative measures with drug treatment should be taken in individuals with a high risk of developing CVD (primary prevention), and to prevent recurrence of events in those with established CVD (secondary prevention).
Some patients cannot tolerate statins, but there are several other classes of drugs that can lower LDL cholesterol. People without CVD People without a history of cardiovascular disease (CVD) also benefit from cholesterol-lowering therapy, although the goal is generally not as aggressive as in people with CVD. The decision of whether to
Comments